Alentis Therapeutics: Positive Results from Single Ascending

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) ALE.F02 found to be well tolerated at all doses with a good safety profile and

Related Keywords

France , Switzerland , Nathalie Graf Tschupp , Kostenloser Wertpapierhandel , Roberto Iacone , Markus Meyer , French National Institute Of Health Inserm , University Of Strasbourg , Consilium Strategic Communications International , Alentis Therapeutics , Thomas Baumert , French National Institute , Strategic Communications , Jane Elliott Matthew Cole Ashley Tapp , Valentis , Herapeutics , Positive , Results , Rom , Single , Ascending , Nose , Hase , Study , Targeting , Claudin ,